Corcept Therapeutics Incorporated (NASDAQ:CORT) Receives $70.83 Average Price Target from Analysts

Posted by Geri Gentry on May 19th, 2026

Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) have received an average rating of “Moderate Buy” from the eight brokerages that are currently covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation, four have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $70.8333.

A number of equities analysts have recently commented on the stock. Zacks Research raised shares of Corcept Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, May 4th. HC Wainwright increased their target price on shares of Corcept Therapeutics from $60.00 to $75.00 and gave the stock a “buy” rating in a research report on Monday, May 4th. Piper Sandler increased their target price on shares of Corcept Therapeutics from $73.00 to $88.00 and gave the stock an “overweight” rating in a research report on Friday, May 1st. Truist Financial upgraded shares of Corcept Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. Finally, Wolfe Research upgraded shares of Corcept Therapeutics from an “underperform” rating to a “peer perform” rating in a research report on Thursday, March 26th.

View Our Latest Stock Analysis on CORT

Corcept Therapeutics Stock Performance

NASDAQ:CORT opened at $55.12 on Friday. The company has a 50-day moving average of $42.75 and a 200-day moving average of $52.84. The company has a market capitalization of $5.92 billion, a price-to-earnings ratio of 157.49 and a beta of 0.36. Corcept Therapeutics has a 52 week low of $28.66 and a 52 week high of $91.00.

Corcept Therapeutics (NASDAQ:CORT – Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The biotechnology company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.19). The business had revenue of $164.90 million for the quarter, compared to the consensus estimate of $185.83 million. Corcept Therapeutics had a return on equity of 7.40% and a net margin of 6.14%.Corcept Therapeutics’s revenue was up 4.9% on a year-over-year basis. During the same period in the previous year, the business posted $0.17 earnings per share. Sell-side analysts forecast that Corcept Therapeutics will post 0.48 EPS for the current year.

Insider Buying and Selling

In other news, Director G Leonard Baker, Jr. bought 100,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 17th. The stock was acquired at an average price of $33.14 per share, for a total transaction of $3,314,000.00. Following the transaction, the director directly owned 1,146,631 shares of the company’s stock, valued at $37,999,351.34. This trade represents a 9.55% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Joseph K. Belanoff sold 26,198 shares of the stock in a transaction dated Wednesday, March 25th. The stock was sold at an average price of $50.07, for a total transaction of $1,311,733.86. Following the sale, the chief executive officer owned 2,918,326 shares of the company’s stock, valued at $146,120,582.82. This trade represents a 0.89% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 86,198 shares of company stock worth $3,887,769 in the last quarter. 20.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Corcept Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CORT. Royal Bank of Canada increased its position in Corcept Therapeutics by 18.9% in the 1st quarter. Royal Bank of Canada now owns 15,385 shares of the biotechnology company’s stock valued at $1,757,000 after acquiring an additional 2,444 shares in the last quarter. Amundi acquired a new stake in Corcept Therapeutics in the 1st quarter valued at about $450,000. NewEdge Advisors LLC acquired a new stake in Corcept Therapeutics in the 1st quarter valued at about $518,000. EverSource Wealth Advisors LLC increased its position in Corcept Therapeutics by 273.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,441 shares of the biotechnology company’s stock valued at $106,000 after acquiring an additional 1,055 shares in the last quarter. Finally, Marshall Wace LLP increased its position in Corcept Therapeutics by 795.3% in the 2nd quarter. Marshall Wace LLP now owns 46,200 shares of the biotechnology company’s stock valued at $3,391,000 after acquiring an additional 41,040 shares in the last quarter. Institutional investors and hedge funds own 93.61% of the company’s stock.

Corcept Therapeutics Company Profile

(Get Free Report)

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.